Pharmexa presents new data from two experimental flu vaccines on international vaccine conference

Pharmexa's abstract ”T-Lymphocyte Epitope Based Vaccine for Pandemic Influenza”
has been selected for oral presentation at the international scientific
conference “Vaccine Congress” which takes place in Amsterdam from 7-9th
December 2007. Pharmexa's hypothesis is that vaccines based on conserved
cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) influenza-derived
epitopes will induce immune responses with the capability to control influenza
virus infections. A potential unique advantage of this type of vaccine is that
it may induce immune responses that target the variant influenza viruses that
emerge without redesign and reformulation. 

Furthermore, Pharmexa's abstract ”Influenza H5 Vaccine: In Need of “Help”” has
also been selected for presentation. A recombinant protein vaccine based on the
H5 influenza virus surface protein could be a highly attractive product due to
ease of manufacture and long-term stability. However, similar recombinant
protein vaccine candidates have proven to be suboptimal in terms of
immunogenicity and require repeated administration with high doses. Pharmexa's
hypothesis is that the immunogenicity of a recombinant protein H5 vaccine can
be increased through the addition of the potent “Universal” helper epitope,
PADRE®. 

At the conference, Pharmexa will present data from these two novel influenza
vaccine concepts, which combine Pharmexa's long standing expertise within the
field of recombinant protein vaccines with its patented Epitope Identification
System (EIS®) and poly-epitope DNA vaccine technologies. 

Hørsholm, September 7, 2007


Jakob Schmidt
Chief Executive Officer

Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525 
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558 


Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and
Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs
approximately 105 people and is listed on the Copenhagen Stock Exchange under
the trading symbol PHARMX.